Savarino 2013

Methods	Open‐label, randomised, controlled trial
Participants	Adult patients with ileal or ileocolonic CD undergoing resection (N = 51) Exclusion criteria: more than 10 years of Crohn's disease requiring first resection for short (10 cm) fibrostenotic stricture, macroscopically active disease not resected during surgery, or the presence of a stoma
Interventions	Adalimumab 160/80 mg at weeks 0 and 2, followed by 40 mg every 2 weeks for 2 years (n = 16) Azathioprine 2.0 mg/kg/day for 2 years (n = 17) Mesalamine 3 g/day for 2 years (n = 18)
Outcomes	Primary outcome: the proportion of patients with endoscopic and clinical recurrence at 2 years Secondary outcomes: quality of life (IBD‐Q), adverse events
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer‐generated randomisation
Allocation concealment (selection bias)	Low risk	"Patient allocation was concealed and performed by an independent nurse not involved with the trial"
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label
Incomplete outcome data (attrition bias) All outcomes	Low risk	One patient withdrew from the adalimumab group due to atopic dermatitis Two patients withdrew from the azathioprine group due to a severe exacerbation of Crohn's disease or an adverse event (severe abdominal pain and increase of pancreatic enzymes Two patients withdrew from the 5‐ASA group due to severe exacerbation of Crohn's disease
Selective reporting (reporting bias)	Low risk	Appropriate data reported
Other bias	Low risk	None apparent